10.1021/jm950803a
The research focuses on developing analogs of thymopentin, an immunomodulating drug with a short half-life in plasma, to enhance its stability while retaining its biological activity. Thymopentin (TP-5) is a pentapeptide with the sequence Arg-Lys-Aspartic Acid-Val-Tyrosine. The parent compound is known for its immunomodulatory properties but has a short half-life in plasma. This study aimed to develop analogs with improved stability while retaining activity. Hydrogen fluoride (HF), a strong acid (HF), is used in the final step to cleave the peptide from the resin and remove any remaining protecting groups, resulting in the final pseudopeptide analog. Ruthenium(IV) Oxide (RuO2), an oxidizing agent (RuO2), is used in combination with sodium periodate (NaIO4) to oxidize olefinic bonds in the synthesis of pseudopeptides, converting them to the desired ketone or acid products. The study concludes that while these modifications improved stability, they often came at the cost of reduced binding affinity, highlighting the trade-offs in designing analogs with both enhanced stability and retained biological activity.